Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine

Published:2024-09-02 Issue: Volume: Page:
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Hamadani Mehdi¹^ORCID,Lucero Melanie²,DeVos Jakob D³,Chen Lei²

Affiliation:

1. Division of Hematology and Oncology & Center for International Blood and Marrow Transplant Research Medical College of Wisconsin Milwaukee Wisconsin USA

2. Health Economics and Outcomes Research ADC Therapeutics New Providence New Jersey USA

3. Center for International Blood and Marrow Transplant Research Medical College of Wisconsin Milwaukee Wisconsin USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.993

Reference7 articles.

1. The antibody‐drug conjugate loncastuximab tesirine for the treatment of diffuse large B‐cell lymphoma;Calabretta E;Blood,2022

2. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

3. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

4. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

5. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP